A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

Core Inclusion Criteria: * At least one lesion that is measurable by RECIST 1.1 at baseline (within 6 weeks prior to start of study treatment). * Mandatory paired biopsies; Patients must have at least one lesion suitable for biopsy at screening * Adequate organ and marrow function * Female patients of childbearing potential must have a negative pregnancy test prior to start of dosing * Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use a highly effective method of contraception during the study from the time of treatment initiation, and for at least 5 months after the last dose of study drug. Module 1 (PDAC) Specific Inclusion Criteria * Histological documentation of advanced (unresectable)/metastatic (Stage III/IV) PDAC, with documented loss of function tumour mutation in RNF43 * Patients must have received one prior systemic treatment for advanced (unresectable)/metastatic PDAC (Stage III/IV), with clear evidence of radiological disease progression * Patients must be enrolled and receive first dose of study treatment within 6 weeks of radiologically confirmed progression * Karnofsky performance status ≥70. Module 2 and Module 3 (BTC) Specific Inclusion Criteria * Histological documentation of advanced (unresectable)/metastatic (Stage III/IV) BTC (intrahepatic or extrahepatic cholangiocarcinoma, ampulla of Vater, or gallbladder cancer) * Patients must have received one prior systemic treatment for…